Publication: A New Versatile Platform for Assessment of Improved Cardiac Performance in Human-Engineered Heart Tissues.
dc.contributor.author | Ribeiro, Marcelo C | |
dc.contributor.author | Rivera-Arbelaez, Jose M | |
dc.contributor.author | Cofiño-Fabres, Carla | |
dc.contributor.author | Schwach, Verena | |
dc.contributor.author | Slaats, Rolf H | |
dc.contributor.author | Ten Den, Simone A | |
dc.contributor.author | Vermeul, Kim | |
dc.contributor.author | van den Berg, Albert | |
dc.contributor.author | Perez-Pomares, Jose M | |
dc.contributor.author | Segerink, Loes I | |
dc.contributor.author | Guadix, Juan A | |
dc.contributor.author | Passier, Robert | |
dc.contributor.funder | Ministry of Education, Culture, and Science of the government of the Netherlands | |
dc.contributor.funder | Dutch Heart Foundation | |
dc.contributor.funder | Consejería de Salud, Junta de Andalucía | |
dc.contributor.funder | Spanish Ministerio de Ciencia, Innovación y Universidades | |
dc.date.accessioned | 2023-05-03T14:11:26Z | |
dc.date.available | 2023-05-03T14:11:26Z | |
dc.date.issued | 2022-02-01 | |
dc.description.abstract | Cardiomyocytes derived from human pluripotent stem cells (hPSC-CMs) hold a great potential as human in vitro models for studying heart disease and for drug safety screening. Nevertheless, their associated immaturity relative to the adult myocardium limits their utility in cardiac research. In this study, we describe the development of a platform for generating three-dimensional engineered heart tissues (EHTs) from hPSC-CMs for the measurement of force while under mechanical and electrical stimulation. The modular and versatile EHT platform presented here allows for the formation of three tissues per well in a 12-well plate format, resulting in 36 tissues per plate. We compared the functional performance of EHTs and their histology in three different media and demonstrated that tissues cultured and maintained in maturation medium, containing triiodothyronine (T3), dexamethasone, and insulin-like growth factor-1 (TDI), resulted in a higher force of contraction, sarcomeric organization and alignment, and a higher and lower inotropic response to isoproterenol and nifedipine, respectively. Moreover, in this study, we highlight the importance of integrating a serum-free maturation medium in the EHT platform, making it a suitable tool for cardiovascular research, disease modeling, and preclinical drug testing. | |
dc.description.version | Si | |
dc.identifier.doi | 10.3390/jpm12020214 | |
dc.identifier.issn | 2075-4426 | |
dc.identifier.pmc | PMC8877418 | |
dc.identifier.pmid | 35207702 | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877418/pdf | |
dc.identifier.unpaywallURL | https://www.mdpi.com/2075-4426/12/2/214/pdf?version=1644908386 | |
dc.identifier.uri | http://hdl.handle.net/10668/21372 | |
dc.issue.number | 2 | |
dc.journal.title | Journal of personalized medicine | |
dc.journal.titleabbreviation | J Pers Med | |
dc.language.iso | en | |
dc.organization | Centro Andaluz de Nanomedicina y Biotecnología-BIONAND | |
dc.organization | Instituto de Investigación Biomédica de Málaga-IBIMA | |
dc.page.number | 16 | |
dc.provenance | Realizada la curación de contenido 07/08/2024 | |
dc.pubmedtype | Journal Article | |
dc.relation.projectID | LSHM19004 | |
dc.relation.projectID | TOP-00812-98-17061 | |
dc.relation.projectID | ERA-CVD 2016T092 | |
dc.relation.projectID | PIER-0084-2019 | |
dc.relation.projectID | RTI2018-095410-BI00 | |
dc.relation.projectID | RD16/0011/0030 | |
dc.rights | Attribution 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | cardiac performance | |
dc.subject | contractile force | |
dc.subject | engineered heart tissues | |
dc.subject | hPSC-CMs | |
dc.subject | serum-free | |
dc.subject | versatile platform | |
dc.subject.decs | Cardiopatías | |
dc.subject.decs | Células madre pluripotentes | |
dc.subject.mesh | Myocytes, cardiac | |
dc.subject.mesh | Isoproterenol | |
dc.subject.mesh | Nifedipine | |
dc.subject.mesh | Triiodothyronine | |
dc.subject.mesh | Insulin-like growth factor I | |
dc.subject.mesh | Myocardium | |
dc.subject.mesh | Pluripotent stem cells | |
dc.subject.mesh | Electric stimulation | |
dc.subject.mesh | Physical functional performance | |
dc.subject.mesh | Dexamethasone | |
dc.subject.mesh | Heart diseases | |
dc.subject.mesh | Dexametasona | |
dc.subject.mesh | Estimulación eléctrica | |
dc.subject.mesh | Factor I del crecimiento similar a la insulina | |
dc.subject.mesh | Isoproterenol | |
dc.subject.mesh | Miocardio | |
dc.subject.mesh | Miocitos cardíacos | |
dc.subject.mesh | Nifedipino | |
dc.subject.mesh | Rendimiento físico funcional | |
dc.subject.mesh | Triyodotironina | |
dc.title | A New Versatile Platform for Assessment of Improved Cardiac Performance in Human-Engineered Heart Tissues. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 12 | |
dspace.entity.type | Publication |